Cytiva Launches Supor Prime Filters for Enhanced Biologic Drug Production

Cytiva has launched its Supor Prime sterilising grade filters to meet the filtration requirements of clients that produce biologic pharmaceuticals with high concentrations. The Supor Prime filter is intended to lower early blockages, increase yields, and minimise filtering loss expenses for drug makers.

High-concentration biologics are becoming more and more popular due to the increased desire for self-administered subcutaneous medications that eliminate the need for intravenous injections at clinics and hospitals.

large-concentration biologic medications are more challenging to filter due to their complicated formulation and consistency, and their large particle load frequently causes early filter blockage. In order to overcome this difficulty, medication makers have frequently responded by adding or enlarging their filters; nevertheless, doing so might result in higher hold-up volumes and expensive drug product losses.

With a high throughput capacity for high-concentration biologic feeds up to 220 grammes per litre of concentration and 30 centipoise viscosity, Cytiva's Supor Prime filters are engineered to maximise pharma product recovery in the latter stages of manufacture. Additionally, the filters are made to scale up from commercial manufacture to clinical development.